Oklahoma Senate Bill SB1483

Oklahoma 2026 Regular Session

• Introduced: 2/2/26
• Refer: 2/3/26

Caption

Civil liability; making vaccine manufacturer liable under certain conditions; directing certain relief. Effective date.

Impact

If enacted, SB1483 would significantly alter the legal landscape surrounding vaccine manufacturers in Oklahoma. It empowers individuals to bring forth legal actions against manufacturers for injuries caused by their vaccines, potentially leading to an increase in litigation against these companies. The specified time frame allowing individuals to file a claim would be within three years of the injury, marking a substantial shift in accountability and responsibilities for vaccine manufacturers operating in the state. This legislation could enhance consumer protections and hold companies accountable for the adverse effects caused by their products.

Summary

Senate Bill 1483, introduced by Senator Rosino, focuses on the civil liability of vaccine manufacturers. The bill establishes that if a vaccine is advertised in Oklahoma and subsequently causes harm or injury to an individual, the vaccine manufacturer can be held liable. This creates a new pathway for individuals to seek damages directly from manufacturers if they are harmed by a vaccine that was promoted through advertising channels, such as television, radio, or digital media. Notably, the bill excludes interactions between healthcare providers and patients from this definition, aiming to limit the scope of liability primarily to advertising practices.

Contention

The introduction of SB1483 may raise several points of contention in legislative discussions. Supporters might argue that this bill offers necessary protections to individuals harmed by vaccines, fostering accountability in vaccine marketing practices. However, opponents could raise concerns about the implications on vaccine manufacturers, citing potential discouragement of vaccine innovation and availability due to the increased liability risks. There could also be discussions about how this bill intersects with existing federal protections and regulations surrounding vaccine manufacturers, which could complicate state-level liabilities.